Replies to post #3931 on ImClone Systems Inc (formerly IMCL)

[DewDiligence]

>Why is IMCL patenting a humanized version of C225, when it has a fully human (phage-display-derived antibody) in clinical trials (phase II/III)? If anyone has any insight on this please let me know.<

To prevent another company from competing with Erbitux by using a humanized Erbitux-like drug.